Bionovo

Bionovo highlights new assay data on menopausal drug

Published in Telemedicine Week, July 4th, 2006

Bionovo, Inc., (BNVI) released new data on the company's lead drug candidate, MF101, for the treatment of vasomotor symptoms, such as hot flashes and night sweats, associated with menopause at the American Society for Mass Spectroscopy 54th Annual Meeting in Seattle.

Bionovo researchers hypothesize that estrogen receptor beta (ERBeta)-selective estrogens may be a safer alternative for women to treat menopausal symptoms, because they do not cause proliferation of breast cancer or uterine cells like estrogens used in current hormone replacement therapy (HRT) regimens.

Bionovo has isolated several key compounds from MF101 that show ERBeta-selectivity in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Telemedicine Week

Source: Telemedicine Week (2006-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry